|
Thomas Petersen MD, PhD
Vice President, Regenerative Medicine
United Therapeutics
USA
|
Dr. Thomas Petersen is Vice President of Regenerative Medicine for United Therapeutics. He is responsible for the management of a regenerative medicine program focused on cell-based therapies and transplantable lung tissues for end-stage pulmonary diseases. He directs the scientific and technical activities of an active R&D laboratory and oversees internal scientific programs and external scientific collaborations. He oversaw the preclinical and early clinical development of an MSC-derived exosome product, which resulted in one of the first successful IND clearances and clinical trials of a therapeutic MSC-derived exosome product in the US.
Dr. Petersen earned his BSE in Electrical Engineering from Princeton University, and his MD and PhD in Biomedical Engineering from Duke University. Prior to joining United Therapeutics, he explored whether lung tissue can be regenerated in vitro and saw results suggesting that repopulation of decellularized lung matrix is a viable strategy for lung regeneration, an important step towards the ultimate goal of generating fully functional lungs in vitro. He holds multiple patents involving lung decellularization and recellularization, endothelial progenitor cells and mesenchymal stem cells, and has published in journals including Science, Biomaterials, Journal of Heart and Lung Transplantation, Physical Review Letters, and American Journal of Physiology-Lung Cellular and Molecular Physiology. Among many services, he has reviewed for the Annals of the American Thoracic Society, Cell Transplantation, and Tissue Engineering, and has served on an NIH study section on biomaterials and biointerfaces. He is a member of the Consortium Monitoring Board for the NIH NIDDK ReBuilding a Kidney (a consortium working on optimizing approaches for isolating, expanding and differentiating kidney cell types and their integration into complex structures replicating human kidney function), and is a member of the National Academies of Sciences, Forum on Regenerative Medicine.
Dr. Petersen earned his BSE in Electrical Engineering from Princeton University, and his MD and PhD in Biomedical Engineering from Duke University. Prior to joining United Therapeutics, he explored whether lung tissue can be regenerated in vitro and saw results suggesting that repopulation of decellularized lung matrix is a viable strategy for lung regeneration, an important step towards the ultimate goal of generating fully functional lungs in vitro. He holds multiple patents involving lung decellularization and recellularization, endothelial progenitor cells and mesenchymal stem cells, and has published in journals including Science, Biomaterials, Journal of Heart and Lung Transplantation, Physical Review Letters, and American Journal of Physiology-Lung Cellular and Molecular Physiology. Among many services, he has reviewed for the Annals of the American Thoracic Society, Cell Transplantation, and Tissue Engineering, and has served on an NIH study section on biomaterials and biointerfaces. He is a member of the Consortium Monitoring Board for the NIH NIDDK ReBuilding a Kidney (a consortium working on optimizing approaches for isolating, expanding and differentiating kidney cell types and their integration into complex structures replicating human kidney function), and is a member of the National Academies of Sciences, Forum on Regenerative Medicine.